HC
APLS

Henshaw Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Henshaw Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,595
Closed -$215K – 285
2023
Q4 		$215K Sell
3,595
-3,240
-47% -$164K 0.01% 272
2023
Q3 		$260K Buy
6,835
+3,460
+103% +$152K 0.02% 245
2023
Q2 		$307K Sell
3,375
-3,517
-51% -$303K 0.02% 179
2023
Q1 		$455K Hold
6,892
– – 0.03% 135
2022
Q4 		$356K Hold
6,892
– – 0.02% 152
2022
Q3 		$471K Hold
6,892
– – 0.03% 148
2022
Q2 		$312K Buy
6,892
+1,123
+19% +$51.2K 0.02% 210
2022
Q1 		$293K Sell
5,769
-750
-12% -$33.1K 0.02% 252
2021
Q4 		$308K Buy
+6,519
New +$257K 0.02% 260

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Henshaw Capital's APLS Position: Q1 2024 in Review

Henshaw Capital sold out of Apellis Pharmaceuticals (APLS) in Q1 2024, closing a stake of 3,595 shares — an estimated $215K sold.

Henshaw Capital first reported a position in APLS in Q4 2021 and held it in 9 quarters. The position peaked at $471K in Q3 2022. 302 funds tracked by Wall St. Rank hold APLS as of Q1 2024.

  • Henshaw Capital reported no remaining Apellis Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Henshaw Capital sold 3,595 Apellis Pharmaceuticals shares in Q1 2024, an estimated $215K.
  • Henshaw Capital first reported a position in Apellis Pharmaceuticals in Q4 2021 and held it in 9 quarters.
  • Henshaw Capital's Apellis Pharmaceuticals position peaked at $471K in Q3 2022.
  • 302 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2024.

Based on Henshaw Capital's 13F filing for Q1 2024, filed 28 May 2026.